{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/lacerations/prescribing-information/erythromycin/","result":{"pageContext":{"chapter":{"id":"f4667375-a12d-57c4-a82a-192c500b41bb","slug":"erythromycin","fullItemName":"Erythromycin","depth":2,"htmlHeader":"<!-- begin field c25a102b-00ea-44fa-8890-80c84b4ce84a --><h2>Erythromycin</h2><!-- end field c25a102b-00ea-44fa-8890-80c84b4ce84a -->","summary":"","htmlStringContent":"<!-- begin item 1e89b82a-b34e-426a-ab01-55e5e28e75c4 --><!-- end item 1e89b82a-b34e-426a-ab01-55e5e28e75c4 -->","topic":{"id":"bc1075da-03fb-510a-aafc-42f8402c77bb","topicId":"c455b3ad-86f5-4c2b-a00d-ceb66ba46f46","topicName":"Lacerations","slug":"lacerations","lastRevised":"Last revised in January 2021","chapters":[{"id":"abcb9c5e-8c70-578e-b2f1-2bfe9e0e6dea","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"b3295eac-08d7-597e-9bbf-240c812490a5","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"0f6da996-76f9-5508-aead-4f7d04fc2910","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"3713be7a-1d15-503e-9cdb-6d3afe60f335","slug":"changes","fullItemName":"Changes"},{"id":"d164a0e0-2763-5ec6-8aaa-1f68fe1d381c","slug":"update","fullItemName":"Update"}]},{"id":"e6d917bb-ce9e-58a6-8b13-cf3e389a6aef","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"83820372-5bd1-5e60-a139-cd76615ac683","slug":"goals","fullItemName":"Goals"},{"id":"15606cb7-089f-5a7d-af3f-d4b9c9b0d2be","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"1a9aa28b-0708-5c58-843c-05a09196b471","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"682e483f-7847-5e82-be10-969f896d9533","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"0db2153f-bcb4-5382-9178-92d651a01c4e","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"3929f359-184e-53d4-8aca-a4081b967c1a","slug":"nice-quality-standards","fullItemName":"NICE Quality standards"}]},{"id":"313e7f7d-a625-5b48-a31d-e5f00ca31462","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"0ad26899-0f07-5523-8ea6-17d520df4cc8","slug":"definition","fullItemName":"Definition"},{"id":"e917af1e-ca7f-5ddd-9cb9-1132ce21b4a9","slug":"prevalence","fullItemName":"Prevalence"},{"id":"fe57a056-8e82-56fa-bb79-87f037fb4303","slug":"complications","fullItemName":"Complications"}]},{"id":"e01eac70-aab4-50c3-a90e-7b07194bf1c8","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"c1be68cd-346e-504f-b22f-e8352fc5c3f6","slug":"assessment","fullItemName":"Assessment"}]},{"id":"35a250d2-9a3b-5287-8afa-d73dfc12c39b","fullItemName":"Management","slug":"management","subChapters":[{"id":"9c6adc10-cc7f-5820-b2da-874e89c9b72b","slug":"laceration-low-infection-risk","fullItemName":"Scenario: Laceration - low infection risk"},{"id":"496fa19f-131c-5dd3-8be3-ae041478b608","slug":"laceration-high-infection-risk","fullItemName":"Scenario: Laceration - high infection risk"},{"id":"9204ec1a-d022-5955-9f74-6b4eb51bf9a9","slug":"laceration-infected","fullItemName":"Scenario: Laceration - infected"}]},{"id":"ae2f2d25-ab30-53a1-8eff-d3fb8c5994f9","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"ffdfa8df-e6e7-56b4-99c6-dfe62dda65a2","slug":"co-amoxiclav","fullItemName":"Co-amoxiclav"},{"id":"f4667375-a12d-57c4-a82a-192c500b41bb","slug":"erythromycin","fullItemName":"Erythromycin"},{"id":"8d7c7214-71fc-5171-9875-f310b20c40cb","slug":"clarithromycin","fullItemName":"Clarithromycin"},{"id":"23d49e6f-7a37-5188-8b3f-6b6fdb671019","slug":"metronidazole","fullItemName":"Metronidazole"},{"id":"f3f77580-8498-590e-a7c3-0afbee563567","slug":"flucloxacillin","fullItemName":"Flucloxacillin"},{"id":"8f912e41-1ff8-5fce-b9b4-6b3524e8f79b","slug":"tetanus-booster","fullItemName":"Tetanus booster"}]},{"id":"b1fc897d-bfab-5305-bcf1-70e0f4598e5a","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"18a38028-bff4-54de-948c-9715f3649589","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"0132c748-edac-513b-a351-59a838b07e61","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"b4b28cd4-4652-528e-aa28-23f341c6a31e","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"b86d931b-dadb-55a7-92c8-6cdb81ce5d7f","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"f6695afc-2f21-5bf7-907b-68a0fb3a77c4","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"d4ab79d3-d601-5b9b-b2b5-d3256e138671","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"bc9ca4ec-c56f-5acc-830c-ccf5c31d5f67","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"ae2f2d25-ab30-53a1-8eff-d3fb8c5994f9","slug":"prescribing-information","fullItemName":"Prescribing information"},"subChapters":[{"id":"fecd7c1c-6585-5ec9-b07b-24fa74ef1127","slug":"licensed-doses","fullItemName":"Licensed doses","depth":3,"htmlHeader":"<!-- begin field 5a7dd6dc-b70f-46d9-aa08-a76c015d8afa --><h3>What are the licensed doses?</h3><!-- end field 5a7dd6dc-b70f-46d9-aa08-a76c015d8afa -->","summary":"","htmlStringContent":"<!-- begin item 2c5cbf70-d01d-4903-b745-a76c015d86c0 --><!-- begin field 674c6691-18f8-4027-a258-a76c015d8afa --><ul><li><strong>Prescribe erythromycin for 5–7 days. The licensed oral doses are:</strong><ul><li><strong>Neonates </strong>— 12.5 mg/kg every 6 hours.</li><li><strong>Children aged 1 month to 1 year </strong>— 125 mg four times daily <em>or </em>250 mg twice daily. In severe infection, dose may be increased to 250 mg four times daily.</li><li><strong>Children aged 2 years to 7 years </strong>— 250 mg four times daily <em>or</em> 500 mg twice daily. In severe infection, dose may be increased to 500 mg four times daily.</li><li><strong>Adults and children aged 8 years and over </strong>— 250–500 mg four times daily <em>or </em>500 mg–1000 mg twice daily. In severe infection, dose may be increased to 500 mg–1000 mg four times daily.</li></ul></li><li><strong>In people with severe renal impairment, </strong>prescribe a maximum daily dose of 1.5 g.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/lacerations/references/\">BNF 73, 2017</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/lacerations/references/\">BNF for Children, 2017</a>]</p><!-- end field 674c6691-18f8-4027-a258-a76c015d8afa --><!-- end item 2c5cbf70-d01d-4903-b745-a76c015d86c0 -->","subChapters":[]},{"id":"4012b23d-94eb-55c2-b042-fda9cb210719","slug":"contraindications-cautions","fullItemName":"Contraindications and cautions","depth":3,"htmlHeader":"<!-- begin field 7445199a-17c2-4b77-87d6-a76c015ddc90 --><h3>What are the contraindications and cautions?</h3><!-- end field 7445199a-17c2-4b77-87d6-a76c015ddc90 -->","summary":"","htmlStringContent":"<!-- begin item b8aa8490-9123-44e3-a4a1-a76c015dd890 --><!-- begin field 62aa7c58-68dc-41e2-853b-a76c015ddc90 --><ul><li><strong>Do not prescribe erythromycin</strong> <strong>to people with</strong><ul><li>Porphyria.</li><li>A history of QT interval prolongation or ventricular cardiac arrhythmia.</li><li>Conditions that predispose to QT interval prolongation such as electrolyte disturbances and people taking drugs that prolong the QT interval</li></ul></li><li><strong>Prescribe erythromycin with caution</strong> <strong>in:</strong><ul><li><strong>People with:</strong><ul><li>Impaired hepatic function — erythromycin is principally excreted by the liver. </li><li>Renal impairment — give a maximum of 1.5 g daily in severe renal impairment (due to the risk of ototoxicity). </li><li>Myasthenia gravis — macrolides may aggravate weakness symptoms.</li></ul></li><li><strong>People concomitantly receiving:</strong><ul><li>Hepatotoxic drugs — erythromycin is principally excreted by the liver.</li></ul></li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/lacerations/references/\">ABPI, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/lacerations/references/\">BNF 73, 2017</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/lacerations/references/\">MHRA, 2020</a>]</p><!-- end field 62aa7c58-68dc-41e2-853b-a76c015ddc90 --><!-- end item b8aa8490-9123-44e3-a4a1-a76c015dd890 -->","subChapters":[]},{"id":"fa2f7394-4d26-5290-aa5b-3ec7152aef1f","slug":"adverse-effects","fullItemName":"Adverse effects","depth":3,"htmlHeader":"<!-- begin field 1d35ed9c-0518-4ee3-a04d-a76c015e1401 --><h3>What are the adverse effects?</h3><!-- end field 1d35ed9c-0518-4ee3-a04d-a76c015e1401 -->","summary":"","htmlStringContent":"<!-- begin item 15a6c3a4-5381-4614-b63b-a76c015e1134 --><!-- begin field 5426195c-d22a-4a6f-8a22-a76c015e1401 --><ul><li><strong>Gastrointestinal adverse effects, </strong>such as nausea, vomiting, and diarrhoea, are common in people taking erythromycin.<ul><li>Consider pseudomembranous colitis (an acute, exudative colitis caused by <em>Clostridium difficile</em>) if a person develops severe diarrhoea during or after treatment with erythromycin. For more information, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/diarrhoea-antibiotic-associated/\">Diarrhoea - antibiotic associated</a>.</li></ul></li><li><strong>Hepatic dysfunction,</strong> including increased liver enzymes and cholestatic hepatitis (with or without jaundice), has been reported with this drug (uncommon).</li><li><strong>Arrhythmias, pancreatitis, QT interval prolongation, Stevens-Johnson syndrome, and toxic epidermal necrolysis</strong> have rarely been reported.</li><li><strong>Reversible hearing loss</strong> (sometimes with tinnitus) can occur after large doses of erythromycin (frequency unknown).</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/lacerations/references/\">ABPI, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/lacerations/references/\">BNF 73, 2017</a>] </p><!-- end field 5426195c-d22a-4a6f-8a22-a76c015e1401 --><!-- end item 15a6c3a4-5381-4614-b63b-a76c015e1134 -->","subChapters":[]},{"id":"8ea324fa-7014-5aed-8b7a-3e4e5d7c9adc","slug":"drug-interactions","fullItemName":"Drug interactions","depth":3,"htmlHeader":"<!-- begin field d72852c7-3cca-490c-b6a0-a76c015e36e9 --><h3>What drug interactions are associated with erythromycin?</h3><!-- end field d72852c7-3cca-490c-b6a0-a76c015e36e9 -->","summary":"","htmlStringContent":"<!-- begin item aca94092-da3f-49a4-a054-a76c015e353d --><!-- begin field 002f12ce-2d55-4fbc-96a4-a76c015e36e9 --><ul><li><strong>The following drugs are contraindicated (or should be avoided) during treatment with erythromycin:</strong><ul><li><strong>Amisulpride </strong>— increased risk of ventricular arrhythmias.</li><li><strong>Colchicine </strong>— erythromycin possibly increases risk of colchicine toxicity. Suspend or reduce dose of colchicine; avoid concurrent use in hepatic or renal impairment.</li><li><strong>Cytochrome P450 CYP3A4 inducers (such as rifampicin, phenytoin, carbamazepine, phenobarbital, and St John's Wort) </strong>— these drugs may induce the metabolism of erythromycin, leading to sub-therapeutic levels of erythromycin and a decreased effect. The induction decreases gradually during two weeks after discontinued treatment with the CYP3A4 inducer. Do not prescribe erythromycin during (and for two weeks after) treatment with a CYP3A4 inducer.</li><li><strong>Domperidone </strong>— erythromycin increases plasma concentration of domperidone (increased risk of ventricular arrhythmias).</li><li><strong>Eletriptan </strong>— erythromycin increases plasma concentration of eletriptan (risk of toxicity).</li><li><strong>Ergot alkaloids </strong>— increased risk of ergotism. </li><li><strong>Ivabradine </strong>— increased risk of ventricular arrhythmias.</li><li><strong>Mizolastine </strong>— erythromycin inhibits metabolism of mizolastine.</li><li><strong>Pimozide </strong>— possible increased risk of ventricular arrhythmias.</li><li><strong>Quetiapine </strong>— erythromycin increases plasma concentration of quetiapine. </li><li><strong>Reboxetine.</strong></li><li><strong>Saquinavir </strong>— increased risk of ventricular arrhythmias.</li><li><strong>Simeprevir </strong>— plasma concentration of both drugs increased when erythromycin is given with simeprevir.</li><li><strong>Simvastatin </strong>— increased risk of myopathy as simvastatin is extensively metabolized by cytochrome P450 enzyme CYP3A4, and erythromycin is a potent inhibitor of CYP3A4. </li><li><strong>Telaprevir </strong>— plasma concentration of both drugs possibly increased when erythromycin given with telaprevir (increased risk of ventricular arrhythmias).</li><li><strong>Tolterodine.</strong></li><li><strong>Venlafaxine </strong>— risk of ventricular arrhythmias.</li></ul></li><li><strong>Concurrent treatment with erythromycin</strong><strong> and the following drugs </strong><strong>should be done with caution </strong>(concurrent use should be monitored; dose adjustments may be indicated):<ul><li><strong>Aminophylline and theophylline </strong>— erythromycin increases plasma concentrations of aminophylline and theophylline. These drugs may also reduce absorption of oral erythromycin.</li><li><strong>Calcium channel blockers </strong>— erythromycin possibly inhibits metabolism of verapamil. Hypotension, bradyarrhythmias, and lactic acidosis have been reported.</li><li><strong>Carbamazepine </strong>— erythromycin can increase carbamazepine levels, causing carbamazepine toxicity (which may present as nausea and vomiting, ataxia, and drowsiness). Monitor carbamazepine levels within 3–5 days of starting erythromycin, and adjust the dose accordingly. </li><li><strong>Ciclosporin </strong>— erythromycin inhibits metabolism of ciclosporin (increased plasma concentration).</li><li><strong>Cimetidine </strong>— plasma concentration of erythromycin increased by cimetidine (increased risk of toxicity, including deafness).</li><li><strong>Clopidogrel </strong>— erythromycin possibly reduces antiplatelet effect of clopidogrel.</li><li><strong>Clozapine </strong>— erythromycin possibly increases plasma concentration of clozapine (possible increased risk of convulsions).</li><li><strong>Corticosteroids </strong>— erythromycin possibly inhibits metabolism of corticosteroids.</li><li><strong>Coumarins </strong>— erythromycin enhances anticoagulant effect of coumarins, such as warfarin. Monitor the international normalized ratio (INR) during concurrent treatment, and adjust the warfarin dose accordingly.</li><li><strong>Edoxaban </strong>— erythromycin increases plasma concentration of edoxaban. Reduce dose of edoxaban.</li><li><strong>Rivaroxaban </strong>— erythromycin may increase levels of rivaroxaban, increasing the risk of bleeding. </li><li><strong>Midazolam </strong>— erythromycin inhibits metabolism of midazolam (increased plasma concentration with increased sedation).</li><li><strong>Other statins </strong>— increased risk of myopathy with statins metabolized by cytochrome P450 enzyme CYP3A4.<ul><li>For atorvastatin — avoid concurrent use with erythromycin if possible. Consider temporarily stopping atorvastatin during short-term treatment with erythromycin. If concurrent use cannot be avoided, prescribe the lowest starting dose of atorvastatin (10 mg) and advise the person to report any muscle pain, tenderness, or weakness.</li><li>For pravastatin — prescribe erythromycin with caution and advise the person to seek medical advice if they experience symptoms of myopathy (for example muscle pain, tenderness, or weakness).</li><li>Clinically significant interaction with erythromycin is not expected for rosuvastatin and fluvastatin. Nevertheless, advise the person to report any muscle pain, tenderness, or weakness. </li></ul></li><li><strong>Rifabutin </strong>— erythromycin possibly increases plasma concentration of rifabutin (increased risk of toxicity). Reduce rifabutin dose.</li><li><strong>Sirolimus </strong>— plasma concentrations of both drugs are increased when erythromycin is given with sirolimus.</li><li><strong>Tacrolimus </strong>— erythromycin increases plasma concentration of tacrolimus.</li><li><strong>Zopiclone</strong> — erythromycin has been reported to decrease the clearance of zopiclone, leading to a possible increased risk in the effects of zopiclone. </li></ul></li><li><strong>Oral hormonal contraception </strong>— additional contraceptive precautions are <em>not </em>required during or after courses of erythromycin.<ul><li>However, advise women on the importance of correct contraceptive practice if they experience vomiting or diarrhoea. For further information, see the sections on vomiting and diarrhoea in the CKS topics on <a class=\"topic-reference external-reference\" href=\"/topics/contraception-combined-hormonal-methods/\">Contraception - combined hormonal methods</a> and <a class=\"topic-reference external-reference\" href=\"/topics/contraception-progestogen-only-methods/\">Contraception - progestogen-only methods</a>.</li></ul></li><li><strong>For a complete </strong><strong>list of possible drug interactions of erythromycin</strong><strong>, </strong>see the <a href=\"http://scribe.clarity.co.uk/www.medicines.org.uk/emc\" data-hyperlink-id=\"cb1003bf-fece-4fb7-9aed-a9900000d6a9\">electronic Medicines Compendium</a> (eMC) and the <a href=\"https://bnf.nice.org.uk/\" data-hyperlink-id=\"f546bb1d-c746-4e4d-97ac-a9900000d6ce\">British National Formulary</a> (BNF).</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/lacerations/references/\">ABPI, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/lacerations/references/\">BNF 72, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/lacerations/references/\">Preston, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/lacerations/references/\">FSRH, 2017</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/lacerations/references/\">MHRA, 2020</a>]</p><p> </p><!-- end field 002f12ce-2d55-4fbc-96a4-a76c015e36e9 --><!-- end item aca94092-da3f-49a4-a054-a76c015e353d -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}